Ortho Evra, the first contraceptive patch approved in the United States, was discontinued from the market around 2014, but not because the FDA pulled it for safety reasons. The FDA formally confirmed that Ortho Evra “was not withdrawn from sale for reasons of safety or effectiveness.” The manufacturer, Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), chose to stop marketing it. While no official reason was announced, the decision came after years of safety controversies, thousands of lawsuits, and the arrival of a generic competitor.
The Estrogen Problem Behind the Controversy
The core issue with Ortho Evra was how much estrogen it delivered compared to birth control pills. The patch was designed to release 35 micrograms of estrogen per day, the same amount found in many oral contraceptives. But because the patch delivered hormones through the skin and into the bloodstream continuously, rather than passing through the digestive system first, it produced a very different hormonal profile. Women using Ortho Evra were exposed to about 60% more total estrogen in their blood than women taking a typical 35-microgram pill.
Interestingly, the peak blood level of estrogen was actually about 25% lower with the patch than with the pill. But the sustained, elevated baseline exposure raised concerns about blood clot risk, since estrogen is the primary driver of clot formation with hormonal contraceptives. The FDA required updated labeling to warn about this higher estrogen exposure, and the patch became the subject of intense scrutiny from regulators, researchers, and the press.
Blood Clot Risk and What Studies Found
The fear was straightforward: more estrogen exposure could mean more blood clots. The relationship between estrogen and venous thromboembolism (blood clots in the veins, particularly the legs and lungs) is well established, and critics argued the patch’s pharmacokinetic profile made it inherently riskier than pills. However, the research picture was more complicated than the headlines suggested. A study published in the journal Contraception found that the risk of nonfatal blood clots for the contraceptive patch was similar to the risk for oral contraceptives containing the same dose of estrogen and a related progestin.
Still, the 60% higher total estrogen exposure was difficult to dismiss, and the FDA acknowledged that the overall higher exposure “could potentially translate into a higher VTE risk compared to women using COCs.” This uncertainty kept the product in a difficult position, with some studies suggesting elevated risk and others showing comparable safety.
Lawsuits and Financial Pressure
Whatever the clinical data showed, the legal system delivered a clearer verdict. About 4,000 complaints were filed against Johnson & Johnson by women who alleged Ortho Evra caused blood clots, heart attacks, and strokes. The lawsuits claimed the company failed to properly investigate the patch’s safety and misled the public about the severity of side effects. By the time the dust settled, J&J had paid out more than $68.7 million to resolve hundreds of individual cases, with settlement details for each case kept confidential.
This legal exposure, combined with the ongoing regulatory scrutiny, made Ortho Evra a costly product to defend. While the company never publicly cited litigation as the reason for discontinuation, the financial and reputational burden was substantial.
A Generic Took Its Place
The timing of Ortho Evra’s exit also coincided with the approval of Xulane, a generic version of the patch made by Mylan (now Viatris). Xulane contains the same active ingredients at the same doses and has the same estrogen delivery profile, including the 60% higher total estrogen exposure compared to oral pills. It is, for all practical purposes, the same product under a different name.
When a brand-name drug faces generic competition, the manufacturer often stops marketing the original because there’s little profit left in competing with cheaper versions of your own formula. This is a routine business decision across the pharmaceutical industry, and it likely played a significant role in Janssen’s choice to pull Ortho Evra from the market. The FDA’s determination that the withdrawal was “for reasons other than safety or effectiveness” supports this interpretation.
What’s Available Now
If you used Ortho Evra and are looking for a replacement, you have two main options in the U.S. Xulane is the direct generic equivalent, with the same hormones, the same weekly application schedule, and the same estrogen profile. It remains on the market and is widely prescribed.
The other option is Twirla, a newer patch approved by the FDA that was specifically designed to address the estrogen concerns surrounding the original patch. Twirla delivers 30 micrograms of estrogen per day (compared to 35 for Xulane and the former Ortho Evra), making it the lowest-dose estrogen patch available. It also uses a different progestin. For women who want the convenience of a patch but are concerned about estrogen exposure, Twirla offers a lower-dose alternative.
Outside the United States, the brand name Evra (without the “Ortho”) is still sold in countries including Canada, where it is manufactured by Searchlight Pharma. It contains the same active ingredients as the original U.S. product.
Why the Answer Isn’t Simple
The honest answer is that no single reason explains Ortho Evra’s disappearance. The FDA did not force it off the market. The manufacturer did not issue a recall. Instead, a combination of factors converged: persistent safety questions about estrogen exposure, thousands of lawsuits costing tens of millions of dollars, regulatory warnings that made prescribers and patients nervous, and the arrival of a cheaper generic that made the brand financially unviable. Each factor alone might not have been enough, but together they made discontinuation the practical choice.